| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。公司自主研发产品BRUKINSA（百悦泽）实现了中国原研新药出海的“零突破”，并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年，公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外，公司作为承担单位进行了5项国家级科研项目，并在核心期刊上发表了34篇学术论文。 | ||||||||||||||||||||||||
| Main Business | 研究、开发、生产以及商业化创新型药物 | ||||||||||||||||||||||||
| Legal Representative | John V. Oyler | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | -- | ||||||||||||||||||||||||
| Solicitors | 上海市方达律师事务所 | ||||||||||||||||||||||||
| Auditors | 致同会计师事务所（特殊普通合伙）;安永华明会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010-58958058 | ||||||||||||||||||||||||
| Fax No | 010-85148699 | ||||||||||||||||||||||||
| Website | www.beigene.cn | ||||||||||||||||||||||||
| ir@beigene.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 15/12/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -4.950 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 18.530 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 18.460B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |